Treatment results and prognostic factors in Ewing sarcoma

Kutluk M., Yalcin B., Akyuz C., Varan A., Ruacan S., Buyukpamukcu M.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.21, no.7, pp.597-610, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 7
  • Publication Date: 2004
  • Doi Number: 10.1080/08880010490501006
  • Journal Name: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.597-610
  • Hacettepe University Affiliated: Yes

Abstract

Files of 133 children with Ewing sarcoma (median age 10 years) were reviewed. Frequent primary sites were extremities, trunk, pelvis, and cranium. Half of 43 patients with metastases had disease in the lungs. Ten-year overall and event-free survival rates were 31% and 19%, respectively. Five-year overall survival rates were 42% in localized and 15% in metastatic disease (p<.0001); 66% in cases with primary tumors <8 cm and 29% in larger tumors (p=.013). VAC (vincristine, actinomycine D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic localization were related to poor prognosis. Novel therapeutic approaches are needed to produce better results, especially in high-risk patients.